
MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 OF 4 PAGES		
License No.: 06-10957-01	Docket or Reference No.:	
	030-01281	
Amendment No. 43		
	License No.: 06-10957-01	License No.: 06-10957-01 Docket or Reference No.: 030-01281

CONDITIONS

- 10. Licensed material shall be used or stored at the licensee's facilities located at 320 Pomfret Street, Putnam, Connecticut, 06260
- 11. The Radiation Safety Officer (RSO) for this license is William J. Roch.
- 12. Licensed material shall only be used by, or under the supervision of:
 - A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users	Material and Use
Bruce P. Arose, M.D.	10 CFR 35.100,10 CFR 35.200
David Blonder, M.D.	10 CFR 35.100,10 CFR 35.200
William M. Bradbury, M.D.	10 CFR 35.100,10 CFR 35.200
Lisa T. Canter, M.D.	10 CFR 35.100,10 CFR 35.200
Thomas H. Farquhar, M.D., Ph.D.	10 CFR 35.100,10 CFR 35.200
Prasanta K. Karak, M.D.	10 CFR 35.100,10 CFR 35.200
Angabeen S. Khan, M.D.	10 CFR 35.100,10 CFR 35.200
Jennifer C. Logan, M.D.	10 CFR 35.100,10 CFR 35.200
Mrinal Mali, M.D.	10 CFR 35.100,10 CFR 35.200
John Modica, M.D.	10 CFR 35.100,10 CFR 35.200
Michael T. O'Loughlin, M.D.	10 CFR 35.100,10 CFR 35.200
John Opalacz, M.D.	10 CFR 35.100,10 CFR 35.200

NDO FORMATIA				
NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 3 OF 4 PAGES				
MATERIALS LICENSE	License No.: 06-10957-01	Docket or Reference No.: 030-01281		
SUPPLEMENTARY SHEET	Amendment No. 43			
Authorized Users	Material and Use			
Ruben Rock, M.D.	10 CFR 35.100,10 CFR 35.200			
Ronald J. Rosenberg, M.D.	10 CFR 35.100,10 CFR 35.200	Ĭ,,		
Gregory T. Turner, M.D.	10 CFR 35.100,10 CFR 35.200			
Steven R. Urbanski, M.D.	10 CFR 35.100,10 CFR 35.200			
	2			
minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.				

NRC FORM 374A	RM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 4 OF 4 PAGES				
MATERIALS LICENSE	License No.: 06-10957-01	Docket or Reference No.: 030-01281			
SUPPLEMENTARY SHEET	Amendment No. 43				
 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ablifty to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations. A. Application dated December 11, 2015 (excluding procedures) [ML15364A550] B. Letter dated February 16, 2016 [ML16063A218] C. Letter dated April 25, 2016 [ML16123A097] D. Letter received May 31, 2019 [ML19158A111] FOR THE U.S. NUCLEAR REGULATORY COMMISSION					
Date: April 24, 2023	Ву:	Valerie Stowell Region 1			